Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Jul 3;83(3):384–386. doi: 10.1054/bjoc.2000.1239

Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer

L C Verhoog 1, C T M Brekelmans 1, C Seynaeve 1, E J Meijers-Heijboer 2, J G M Klijn 1
PMCID: PMC2374577  PMID: 10917555

Abstract

BRCA1/2 mutation carriers diagnosed with breast cancer have a strongly elevated life-time risk of developing a contralateral tumour. We studied the contralateral breast cancer risk in 164 patients from 83 families with a proven BRCA1 mutation in relation to the age at diagnosis of the first primary breast cancer. In the actuarial outcomes after 10 years’ follow-up, 40% of the 124 BRCA1-patients diagnosed with breast cancer < 50 years had developed contralateral breast cancer, vs 12% of the 40 patients > 50 years at first diagnosis (Plogrank= 0.02). These data suggest that age at diagnosis of the first tumour should be taken into account when prophylactic mastectomy in BRCA1-patients is considered. © 2000 Cancer Research Campaign

Keywords: BRCA1

Full Text

The Full Text of this article is available as a PDF (46.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adami H. O., Bergström R., Hansen J. Age at first primary as a determinant of the incidence of bilateral breast cancer. Cumulative and relative risks in a population-based case-control study. Cancer. 1985 Feb 1;55(3):643–647. doi: 10.1002/1097-0142(19850201)55:3<643::aid-cncr2820550328>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  2. Anderson D. E. Some characteristics of familial breast cancer. Cancer. 1971 Dec;28(6):1500–1504. doi: 10.1002/1097-0142(197112)28:6<1500::aid-cncr2820280623>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  3. Broët P., de la Rochefordière A., Scholl S. M., Fourquet A., Mosseri V., Durand J. C., Pouillart P., Asselain B. Contralateral breast cancer: annual incidence and risk parameters. J Clin Oncol. 1995 Jul;13(7):1578–1583. doi: 10.1200/JCO.1995.13.7.1578. [DOI] [PubMed] [Google Scholar]
  4. Easton D. F., Ford D., Bishop D. T. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet. 1995 Jan;56(1):265–271. [PMC free article] [PubMed] [Google Scholar]
  5. Ford D., Easton D. F., Bishop D. T., Narod S. A., Goldgar D. E. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet. 1994 Mar 19;343(8899):692–695. doi: 10.1016/s0140-6736(94)91578-4. [DOI] [PubMed] [Google Scholar]
  6. Ford D., Easton D. F., Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet. 1995 Dec;57(6):1457–1462. [PMC free article] [PubMed] [Google Scholar]
  7. Ford D., Easton D. F., Stratton M., Narod S., Goldgar D., Devilee P., Bishop D. T., Weber B., Lenoir G., Chang-Claude J. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998 Mar;62(3):676–689. doi: 10.1086/301749. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hislop T. G., Elwood J. M., Coldman A. J., Spinelli J. J., Worth A. J., Ellison L. G. Second primary cancers of the breast: incidence and risk factors. Br J Cancer. 1984 Jan;49(1):79–85. doi: 10.1038/bjc.1984.12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hogervorst F. B., Cornelis R. S., Bout M., van Vliet M., Oosterwijk J. C., Olmer R., Bakker B., Klijn J. G., Vasen H. F., Meijers-Heijboer H. Rapid detection of BRCA1 mutations by the protein truncation test. Nat Genet. 1995 Jun;10(2):208–212. doi: 10.1038/ng0695-208. [DOI] [PubMed] [Google Scholar]
  10. Newman B., Mu H., Butler L. M., Millikan R. C., Moorman P. G., King M. C. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA. 1998 Mar 25;279(12):915–921. doi: 10.1001/jama.279.12.915. [DOI] [PubMed] [Google Scholar]
  11. Peto J., Collins N., Barfoot R., Seal S., Warren W., Rahman N., Easton D. F., Evans C., Deacon J., Stratton M. R. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst. 1999 Jun 2;91(11):943–949. doi: 10.1093/jnci/91.11.943. [DOI] [PubMed] [Google Scholar]
  12. Petrij-Bosch A., Peelen T., van Vliet M., van Eijk R., Olmer R., Drüsedau M., Hogervorst F. B., Hageman S., Arts P. J., Ligtenberg M. J. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet. 1997 Nov;17(3):341–345. doi: 10.1038/ng1197-341. [DOI] [PubMed] [Google Scholar]
  13. Prior P., Waterhouse J. A. Incidence of bilateral tumours in a population-based series of breast-cancer patients. I. Two approaches to an epidemiological analysis. Br J Cancer. 1978 Apr;37(4):620–634. doi: 10.1038/bjc.1978.92. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Robson M., Gilewski T., Haas B., Levin D., Borgen P., Rajan P., Hirschaut Y., Pressman P., Rosen P. P., Lesser M. L. BRCA-associated breast cancer in young women. J Clin Oncol. 1998 May;16(5):1642–1649. doi: 10.1200/JCO.1998.16.5.1642. [DOI] [PubMed] [Google Scholar]
  15. Verhoog L. C., Brekelmans C. T., Seynaeve C., Dahmen G., van Geel A. N., Bartels C. C., Tilanus-Linthorst M. M., Wagner A., Devilee P., Halley D. J. Survival in hereditary breast cancer associated with germline mutations of BRCA2. J Clin Oncol. 1999 Nov;17(11):3396–3402. doi: 10.1200/JCO.1999.17.11.3396. [DOI] [PubMed] [Google Scholar]
  16. Verhoog L. C., Brekelmans C. T., Seynaeve C., van den Bosch L. M., Dahmen G., van Geel A. N., Tilanus-Linthorst M. M., Bartels C. C., Wagner A., van den Ouweland A. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet. 1998 Jan 31;351(9099):316–321. doi: 10.1016/s0140-6736(97)07065-7. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES